Compounds based on the purine structure (10–12) were synthesized which are claimed to bind to the Hsp90 inhibitors strength and inhibit tumor growth, these compounds were known as good candidates for clinical phase studies. This evidence concerns the gene HSP90AA1 and neoplasm.